Third Party Performance Data
To confirm reproducibility and robustness, Trenchant collaborated with Invetech, a global leader in advanced therapy manufacturing and product development, to perform testing using the identical Trenchant prototype platform, cassettes, and protocols.
Study Design
Invetech conducted three independent process runs using fresh human apheresis sourced from healthy donors. All critical unit operations—washing, selection, activation, and transduction were evaluated under controlled laboratory conditions.
Third Party Performance Results
Apheresis Wash Recovery
94.3%
Mean T-cell recovery
Single-step T-cell Selection & Activation Recovery
96.4%
Mean T-cell recovery
98.4%
Mean T-cell purity
Lentiviral Transduction Efficiency
73.6%
Mean GFP-positive cells
Benchmark Comparison
When compared against published data for the current market-leading automated system, the Trenchant prototype demonstrated an approximately 7-fold increase in cumulative gene-modified cell yield, validated both internally and independently.
This performance confirms that Trenchant’s approach can support three-day manufacturing timelines, eliminate ex-vivo expansion, and enable scalable, point-of-care cell therapy production.